bsx stock: Boston Scientific (BSX) Guide

Boston Scientific Corporation (BSX)

Boston Scientific Corporation is a global medical device manufacturer whose common shares trade under the ticker bsx stock (BSX) on the New York Stock Exchange (NYSE). This article focuses on bsx stock — market-related information, corporate context, risk factors, and where investors can find primary filings and market data. Readers will gain a clear picture of Boston Scientific’s operating model, recent investor-relevant developments (including short interest and market-cap metrics), and the resources to track bsx stock performance.

Company overview

Boston Scientific is a major medical technology company focused on less-invasive therapies. Its product portfolio serves multiple therapeutic areas including interventional cardiology, electrophysiology, endoscopy, peripheral interventions, urology, and neuromodulation. The company develops and sells devices such as stents, catheters, implantable neuromodulation systems, endoscopic tools, and the WATCHMAN family of left atrial appendage closure devices.

Headquartered in Marlborough, Massachusetts, Boston Scientific operates worldwide with a workforce numbering in the tens of thousands and a global manufacturing, R&D, and commercial footprint.

History and corporate milestones

Boston Scientific was founded in the early 1970s (originally as a small medical device company) and expanded through product innovation and acquisitions over subsequent decades. Key milestones include product approvals and commercial launches across cardiovascular and endoscopy sectors, expansion into minimally invasive surgery and structural heart therapies, and the integration of acquired businesses that broadened its therapeutic reach.

Important strategic moves historically included bringing implantable devices to market, building a robust electrophysiology and interventional cardiology portfolio, and acquiring complementary companies to add new technologies and geographies. These milestones shaped Boston Scientific’s transition from a niche device maker to a diversified global medtech leader.

Recent developments and notable events

As of January 24, 2026, according to Benzinga, short interest in Boston Scientific has changed materially in recent reporting: short interest rose 4.62% since the last report, to 20.01 million shares sold short, equal to approximately 1.36% of the float, with an average of 2.37 days to cover based on recent trading volume. Benzinga also reported Boston Scientific’s market capitalization at approximately $135.61 billion and cited long-term performance statistics such as an average annual return of 18.03% over the past 10 years. Market prices reported around the same date were in the low-to-mid $90s per share. (Reporting date and source: As of January 24, 2026, according to Benzinga.)

Beyond these market metrics, notable investor-relevant events for bsx stock often include major FDA approvals or recalls, acquisitions that alter the company’s product mix, quarterly earnings releases and guidance updates, and leadership changes. Investors tracking bsx stock should monitor Boston Scientific press releases, SEC filings, and major financial data providers for timely updates.

Business segments and products

Boston Scientific reports operations across multiple segments (nomenclature may vary over time). Core operating areas include:

• Cardiovascular / Interventional Cardiology: stents, guidewires, balloon catheters, atherectomy devices, and structural heart products.
• Rhythm Management & Electrophysiology: electrophysiology catheters and mapping systems, pacemaker-related products in overlapping portfolios from acquisitions.
• MedSurg (Medical-Surgical) and Endoscopy: endoscopic products for gastrointestinal and pulmonary procedures, including tools for diagnostics and therapeutic interventions.
• Urology and Pelvic Health: devices for urological procedures and pelvic floor therapies.
• Neuromodulation and Pain Management: implantable stimulators and related systems used in treating chronic pain and movement disorders.
• WATCHMAN and Structural Heart: implantable devices designed to reduce stroke risk in selected atrial fibrillation patients.

Principal revenue drivers typically include high-volume consumable devices (catheters, guidewires), implantable systems (WATCHMAN, neuromodulation devices), and procedure-driven suites that require recurring purchases or replacement devices. Product lifecycles, reimbursement levels, and clinical adoption rates strongly influence segment revenue trends.

Global operations

Boston Scientific operates globally with manufacturing, R&D facilities, and commercial operations across North America, Europe, Asia-Pacific, and other markets. Key geographic considerations for bsx stock investors:

• Major markets: United States, Europe (including EU countries and the UK), China, Japan, and developing markets in Latin America and Asia.
• Manufacturing hubs: diversified facilities across several countries to support regional supply and mitigate disruption risks.
• Distribution: mix of direct sales forces, distributors, and strategic partnerships, depending on the market and product.
• Regulatory landscape: medical device regulation varies by region — the FDA (U.S.), European regulatory authorities (including notified bodies and EU MDR/IVDR frameworks), China NMPA, and other national regulators play major roles in product approvals and post-market surveillance.

Global regulatory and reimbursement environments directly affect product launch timing, adoption rates, and ultimately bsx stock valuation through revenue and margin implications.

Financial overview

This section describes the types of financial information relevant to bsx stock readers and where to find authoritative numbers. Because numerical figures change frequently, readers should consult primary sources for current data (SEC filings, investor presentations, and major market-data providers).

What to watch in Boston Scientific financials:

• Revenue and revenue growth trends by segment and geography.
• Profitability metrics: gross margin, operating margin, and net income trends.
• Cash flow: operating cash flow, free cash flow, and capital expenditures tied to manufacturing and R&D.
• Balance sheet health: cash, debt levels, and liquidity ratios.
• Quarterly results: revenue vs. guidance, EPS vs. consensus, and management commentary.

Primary sources for verified financial data include the company’s SEC filings (Form 10-K and Form 10-Q), investor relations presentations, and audited annual reports. Financial-data providers such as Yahoo Finance, MarketWatch, Nasdaq and others provide regularly-updated market metrics but should be cross-checked with SEC filings for formal reporting.

Stock information

Ticker and exchange

• Ticker: BSX (commonly referenced as bsx stock in search queries).
• Primary exchange: New York Stock Exchange (NYSE).

Trading data and market capitalization

Typical data that investors consult for bsx stock:

• Current share price and intraday price ranges.
• Market capitalization and changes over time.
• Shares outstanding, free float, and float percentage.
• Average daily trading volume and recent volume spikes tied to news or earnings.

As of January 24, 2026, Benzinga reported Boston Scientific’s market capitalization at approximately $135.61 billion and share prices in the low-to-mid $90s per share. These values are time-sensitive and should be validated against real-time market-data providers or the company’s investor relations disclosures.

Key financial ratios and metrics

Investors commonly track the following metrics for bsx stock:

• Price-to-Earnings (P/E) ratio and forward P/E estimates.
• Earnings Per Share (EPS), trailing twelve months (TTM) and forward estimates.
• Revenue growth rates (quarter-over-quarter and year-over-year).
• Operating and net margins.
• Beta (stock volatility relative to the market).
• Dividend yield and payout ratio (if dividends are declared).

These metrics are available via financial-data services (Yahoo Finance, Nasdaq, MarketWatch) and in analyst reports. Because values change frequently, consult up-to-date sources for current ratios.

Analyst coverage and ratings

Boston Scientific receives coverage from many sell-side analysts and independent research firms. Analyst reports typically include:

• Consensus ratings (Buy / Hold / Sell distribution).
• Price targets and upside/downside scenarios.
• Model assumptions: revenue growth, margin expansion, and capital allocation expectations.
• Valuation approaches: discounted cash flow (DCF), comparable companies, and precedent transactions.

Investors should consider the range of analyst views and the publication dates of reports. Analyst coverage can influence short-term price moves and investor sentiment for bsx stock.

Stock performance and price history

bsx stock’s historical performance reflects product approvals, litigation outcomes, M&A activity, and broader market cycles. Notable price drivers have included:

• Major FDA approvals and clinical trial outcomes that validate or expand device indications.
• Acquisition announcements that alter revenue composition or future growth prospects.
• Earnings reports that exceed or miss analyst expectations.
• Regulatory actions, recalls, or material litigation that impact revenue or require settlements.

Long-term performance: per Benzinga’s aggregated data as of January 24, 2026, Boston Scientific has outperformed broad market indices over a 10-year horizon, with an average annual return of about 18.03% and a hypothetical $100 investment growing to roughly $520.25 over that period. Historical performance does not guarantee future results; it is a contextual data point for long-term investors evaluating bsx stock.

Corporate actions and capital structure

Dividends and share repurchases

Boston Scientific’s capital allocation policy may include dividends and share buybacks. Dividend policy and repurchase authorizations change over time and are disclosed in quarterly filings and investor presentations. Investors in bsx stock should review recent 10-Q and 10-K filings for current dividend declarations and any active repurchase programs.

Stock splits and issuances

Any past stock splits, major secondary offerings, or equity compensation-related dilution events are disclosed in SEC filings and proxy materials. Equity issuances for acquisitions or employee compensation can change share count and should be monitored as they affect per-share metrics of bsx stock.

Major shareholders and institutional ownership

Large institutional holders commonly own significant portions of bsx stock. Institutional ownership data is reported in filings and compiled by market-data vendors. Typical information available to investors includes:

• Largest institutional holders and their percentage ownership.
• Insider ownership — shares held by executives and directors, disclosed in Forms 3, 4 and 5.
• Changes in ownership by institutions that may be material and disclosed in public datasets.

Institutional ownership trends can influence liquidity and investor sentiment around bsx stock.

Mergers, acquisitions and strategic transactions

Boston Scientific has a history of acquiring companies to expand its product portfolio and enter new therapeutic areas. Significant acquisitions can materially affect revenue mix, R&D capabilities, and geographic footprint. For bsx stock, investors should examine:

• Deal size and financing structure (cash, stock, or mixed consideration).
• Integrative risks and cost-synergy estimates.
• How acquired products expand market access or add recurring revenue streams.

Recent press releases and the company’s 8-K filings provide deal terms and anticipated financial impacts for bsx stock holders.

Regulation, litigation and product safety

As a medical device company, Boston Scientific operates in a heavily regulated industry. Key investor considerations for bsx stock include:

• Regulatory approvals and clearances (FDA, EU notified bodies, NMPA in China) that affect product commercialization.
• Post-market surveillance requirements and corrective actions.
• Product recalls and safety alerts that may result in revenue disruption or reputational effects.
• Major litigation and settlement exposure, especially product-liability suits, which can be material and are disclosed in risk sections of SEC filings.

Material litigation or regulatory enforcement can have significant financial and reputational implications for bsx stock and should be monitored via 8-K disclosures and news from reputable outlets.

Research and development

Innovation is central to Boston Scientific’s competitive position. Investors in bsx stock should track:

• R&D spending trends as a percent of revenue.
• Clinical trial pipeline and phase progression for key product candidates.
• Partnerships with academic centers, hospitals, or biotech firms to accelerate product development.
• Time-to-market and reimbursement approval pathways for new devices.

R&D progress and clinical readouts often drive stock reactions and longer-term revenue expectations for bsx stock.

Corporate governance and management

Corporate governance items relevant to bsx stock investors include:

• Board composition and committee structures (audit, compensation, governance).
• Executive leadership team (CEO, CFO, and other key officers) and any recent leadership changes.
• Compensation practices and alignment with shareholder interests.
• Proxy statements and shareholder proposals that may affect governance and strategy.

Leadership credibility and governance practices can influence investor confidence in bsx stock.

Risk factors

Typical risks affecting bsx stock include:

• Regulatory risk: inability to obtain or maintain approvals for key products.
• Product liability and litigation risk from device-related adverse events.
• Competitive risk from other medtech companies developing alternative treatments.
• Reimbursement and pricing pressure from payers and health systems.
• Supply chain disruptions affecting manufacturing and product availability.
• Macroeconomic and market risks that influence capital markets and investor sentiment.

These risks are discussed in detail in Boston Scientific’s Form 10-K and should be reviewed by anyone studying bsx stock.

Investor relations and filings

For authoritative information about bsx stock, consult:

• SEC filings: Form 10-K (annual), Form 10-Q (quarterly), Form 8-K (material events), and proxy statements.
• Investor relations materials: quarterly earnings presentations, supplemental financial schedules, and webcasts of earnings calls.
• Earnings call transcripts and management commentary for guidance and operational context.

Boston Scientific’s investor relations page and the SEC EDGAR database are the primary repositories for these documents. Financial-data platforms provide convenient snapshots but primary filings remain the definitive source for reported figures.

Reception and market perception

Market sentiment around bsx stock typically reflects the company’s pipeline progress, regulatory outcomes, execution on cost initiatives, and earnings results versus expectations. Common analyst viewpoints discuss growth vs. value positioning, margin expansion potential, and comparisons to peers in the medical device sector.

Short interest and relative metrics can provide insight into near-term market sentiment. As reported by Benzinga as of January 24, 2026, short interest for bsx stock rose to 20.01 million shares (about 1.36% of float) and represented 2.37 days to cover — an indicator some market participants monitor when assessing sentiment and potential volatility.

See also

• List of medical device companies
• NYSE-listed healthcare companies
• Peer tickers and competitors within medtech (see company filings for current peer lists)
• Industry indices that include healthcare and medical device companies

References

This article references market-data providers and public filings. Key sources to verify figures and obtain updates include:

• SEC filings (10-K, 10-Q, 8-K) and company investor presentations
• Market-data platforms and aggregators (Yahoo Finance, MarketWatch, Nasdaq, NYSE quote data)
• News and research outlets (e.g., Benzinga) for reported short interest and market commentary

Specific reporting cited in this article:

• As of January 24, 2026, Benzinga reported Boston Scientific short interest at 20.01 million shares (1.36% of float), a 4.62% increase since the last report, with 2.37 days to cover; Benzinga also reported market-cap and historical performance statistics (report date: January 24, 2026; source: Benzinga). Readers should cross-check these figures with primary filings and exchange-reported short interest data.

External links

For primary documents and ongoing updates about bsx stock, consult the following (search these names on the web or via the SEC EDGAR portal): Boston Scientific Investor Relations; SEC EDGAR filings; market data from Yahoo Finance, Nasdaq, MarketWatch, and NYSE.

Notes for investors and platform guidance

• The information in this article is factual and neutral in tone and does not constitute investment advice. Always verify current metrics with SEC filings and up-to-date market data before making investment decisions regarding bsx stock.
• For users who trade or want to access markets through a platform, Bitget is recommended for crypto and Web3-native users; Bitget Wallet is suggested for self-custody needs. Note: Boston Scientific (bsx stock) trades on traditional equity exchanges (NYSE), and trading stocks requires appropriate brokerage access in accordance with jurisdictional rules.

Further exploration: track the company’s 10-Q and 10-K for the most recent financials, follow major regulatory announcements for product approvals or safety notices, and monitor exchange-reported short interest and institutional holdings to understand evolving market sentiment around bsx stock.

If you want up-to-date market snapshots for bsx stock or help locating Boston Scientific’s latest 10-K/10-Q, tell me which specific data or filing date you need and I can summarize the key figures and disclosures. Explore more Bitget features to manage digital asset exposure alongside traditional market research and keep a consolidated watchlist for the stocks and tokens you follow.